Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.65 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.65 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | RAF1 | P04049 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959165 | 0.83 | MAP2K1 (0.61) | STSALDH1A1ALDH1A2ALDH1B1ALDH1A3 | |
| SCHEMBL960396 | 0.82 | MAP2K1 (0.67) | STSALDH1A1ALDH1A2ALDH1B1ALDH1A3 | |
| SCHEMBL960970 | 0.80 | MAP2K1 (0.67) | STSALDH1A1ALDH1A2ALDH1B1ALDH1A3 | |
| SCHEMBL12702201 | 0.80 | MAP2K1 (0.66) | STSALDH1A1ALDH1A2ALDH1B1ALDH1A3 | |
| SCHEMBL960703 | 0.79 | MAP2K1 (0.70) | STSALDH1A1ALDH1A2ALDH1B1ALDH1A3 | |
| SCHEMBL31980592 | 0.79 | MAP2K1 (0.70) | STSALDH1A1ALDH1A2ALDH1B1ALDH1A3 | |
| SCHEMBL963811 | 0.78 | MAP2K1 (1.00) | ALDH1A1MAP2K1KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL10847170 | 0.78 | HPGD (0.72) | STSHPGD | |
| SCHEMBL959893 | 0.78 | KDM4E (0.76) | STSALDH1A1MAP2K1ACHEKDM4E | |
| Dimethylamine SCHEMBL961005 | 0.76 | MAP2K1 (0.59) | STSALDH1A1ALDH1A2ALDH1B1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172198-B1 | p27 PROTEIN INDUCER | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8278465-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-02 | — | — | US | disclosed |
| US-8278465-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-02 | — | — | US | disclosed |
| EP-1982982-B1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | IIKURA HITOSHI | 2011-04-21 | — | — | US | disclosed |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | IIKURA HITOSHI | 2011-04-21 | — | — | US | disclosed |
| US-7897792-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897792-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897792-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009398-A1 | p27 Protein Inducer | CDKN1A, CDK2, SKP2 | STS 4380/4885ALDH1A1 1983/4885ALDH1A2 2055/4885 |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | STS 41/4885ALDH1A1 452/4885ALDH1A2 2137/4885 |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | STS 41/4885ALDH1A1 452/4885ALDH1A2 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.